BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
Thursday, September 17, 2026
📌TL;DR
Vera Therapeutics' ORIGIN 3 final analysis: Trutakna cut kidney disease progression risk 76% over two years (HR 0.24), with zero dialysis, transplant, or death events versus eight on placebo; a supplemental BLA for full approval is planned for Q4 2026.
Novartis ended development of VHB937 (lifonebart) in ALS after the 251 patient Astrals Phase 2 missed its primary and secondary endpoints, and the same day agreed to pay $125 million for Sironax's blood brain barrier delivery platform.
Bristol Myers Squibb and Ono sued Amgen in Delaware over seven Opdivo patents as Amgen's ABP 206 biosimilar heads toward an FDA decision Amgen expects by year end.
Skyhawk's oral SKY-0515 showed a 1.59 point cUHDRS benefit versus an external control at fifteen months in Huntington's disease, in 15 treated patients.
Gilead expanded its six royalty free licenses to cover investigational once yearly lenacapavir for 120 high incidence countries ahead of Phase 3 data.
AMLX closed at $32.63, a thirteenth straight close below the $35.50 offer price, with the greenshoe disclosure window arriving Thursday.
⚡ Executive Takeaway
On Tuesday night we wrote that dated catalysts are the only reliable buyers in this tape, and that a silent bounce in Definium and Corbus would confirm the selloff was liquidity mechanics rather than information. Wednesday ran the experiment for us. Both names bounced without a word of news. Ionis kept bleeding without a filing. And Vera, holding the best evidence package IgA nephropathy has ever produced, was sold for a second straight session. The market is not disputing Vera's data; it is declining to pay for anything without a date attached.
Which is why Vera's most important disclosure this week may not have been the hazard ratio. It was the calendar: a supplemental BLA in the fourth quarter, full approval expected in 2027, 350 start forms in ten weeks. Evidence plus a date is the only currency trading at par this month. Tomorrow the thesis gets its cleanest test yet: Amylyx runs out of silence around Thursday, and Friday the FDA speaks on UX111 whether anyone likes it or not. 👉 Read Full Analysis
🧬 Kidney Disease
Vera printed everything, and the market sold it twice. VERA | VRTX
The final ORIGIN 3 efficacy analysis, released Tuesday morning, is the strongest dataset IgA nephropathy has produced: a 76% reduction in kidney disease progression risk (HR 0.24, p<0.0001), an annualized eGFR decline of 0.6 points per year versus 5.6 for placebo, and zero patients reaching dialysis, transplant, or death through two years versus eight on placebo. Vera will file for full approval in Q4 and disclosed more than 350 patient start forms in ten weeks of launch. The tape's answer: a 9% opening pop on release day that faded to a lower close on ten times normal volume, then another 5.6% down Wednesday to $31.77, no disclosure found. For Vertex, whose povetacicept shares the dual BAFF and APRIL mechanism and faces an FDA decision by November 30, the mechanism just got validated and the commercial bar just got raised in the same breath. Cross trial comparisons carry the usual caveats; the Pro brief runs the endgame math.
🧠 Neuro
Novartis shut one door to the brain and bought another. NVS
Novartis confirmed by spokesperson statement that VHB937 (lifonebart), its TREM2 targeted ALS antibody, missed primary and secondary endpoints in the 251 patient Astrals Phase 2 and that ALS development is over; no figures were released and the Alzheimer's trial of the mechanism continues. Hours later, Sironax announced Novartis exercised its option and will pay $125 million at closing for full global rights to Sironax's blood brain barrier delivery platform, with Sironax keeping three clinical stage programs built on it. That is the fourth Novartis R&D setback we have logged since Labor Day, after pelacarsen, del-desiran, and the rap-cel pause, and the response pattern is becoming legible: buy delivery infrastructure that de risks many programs rather than one more piece of single asset biology. NVS closed flat at $138.70, no cause assigned.
🧪 Huntington's
Skyhawk's number is remarkable. Its denominator is 15.
Skyhawk Therapeutics reported final fifteen month results for SKY-0515, its oral huntingtin lowering splicing modifier: patients improved 1.59 points on cUHDRS versus a weighted external natural history control (p<0.001), with every component significant and average mutant huntingtin reduction above 60% at the 9 mg dose. The caveats are structural, not incidental: 15 treated patients, an external comparator, and an extension design after a 12 week blinded start. The randomized answer is enrolling now in the roughly 600 patient FALCON-HD program. The bigger picture: between this and uniQure's AMT-130 filing, Huntington's has become the proving ground for external control evidence in neurodegeneration, which is exactly the terrain where a company like Novartis just bought a delivery platform.
⚖️ Biosimilars
BMS is suing the biosimilar everyone knew was coming. BMY | AMGN
Bristol Myers Squibb and Ono Pharmaceutical sued Amgen in Delaware over seven Opdivo patents covering the nivolumab molecule and treatment methods, alleging Amgen shorted the biosimilar patent dance on manufacturing detail, per Fierce Pharma's report of the filing. Amgen has said it expects an FDA decision on ABP 206 by the end of 2026; BMS models US biosimilar entry around 2028. Opdivo did $5.9 billion in US revenue last year per BMS's reported results as cited in the coverage, so every month of delay the suit buys is real money. The strategic note: this is the first PD-1 biosimilar fight, and how it resolves will set the template for the entire checkpoint class as the decade's biggest oncology franchises come off patent.
🌍 Global Health
Gilead licensed a formulation that does not exist yet. GILD
Gilead expanded its six royalty free voluntary licenses, held by Dr. Reddy's, Emcure, Eva Pharma, Ferozsons, Hetero, and Mylan, to cover the investigational once yearly formulation of lenacapavir for HIV prevention across 120 high incidence, resource limited countries, while Phase 3 PURPOSE 365 is still running. The release's own context explains the urgency: 1.2 million HIV acquisitions in 2025 and fewer than 4 million people on PrEP against a 21 million target. Licensing manufacturing before pivotal data is a structural bet that annual dosing is the version that finally scales prevention, and it means generic supply could follow approval with minimal lag rather than the usual multi year gap. GILD closed at $147.68, up 0.9%.
📉 The Tape
The bounce we called landed, silently, on schedule. DFTX | CRBP | IONS | AMLX
In Wednesday's edition we wrote that a silent bounce in Definium and Corbus would confirm the liquidity read, and that further Ionis drift without news would stay a positioning tell. Official September 16 closes: DFTX 37.85, up 2.8%, no news found, still below its pre readout 38.89; CRBP 7.26, up 4.9%, no news found; IONS 44.84, down 5.1%, a third straight decline, roughly 12.8% off its September 11 close by our arithmetic, still no disclosure located; SION 7.04, up 2.3%; CTNM 13.76, down 0.4%; BBNX 22.18, up another 15.3% in the second session after the Mint clearance. Elsewhere: AMLX 32.63, down 1.6%, a thirteenth straight close below the $35.50 offer with the greenshoe window arriving Thursday; SRRK 49.37, a third straight post approval decline; RARE 12.88 into Friday's UX111 date; GRAL 75.11 with briefing documents still unposted as of Wednesday night. No cause assigned to any move without a company disclosure.
📋 Quick Hits
Sling Therapeutics raised a $123 million Series C led by Forbion to take linsitinib, its oral IGF-1R inhibitor for thyroid eye disease licensed from Astellas, through Phase 3; first patients are dosed.
Ori Biotech signed a ten year partnership worth up to $120 million with an unnamed company that markets a commercial cell therapy, deploying its automated Iro manufacturing platform.
Legend Biotech named Ingrid Zhang CEO effective September 15; the former Novartis chief commercial officer takes over from interim chief Alan Bash, who returns to president of the Carvykti franchise.
CMS expanded its ACCESS chronic care model to add heart failure, COPD, substance use disorder, and tobacco cessation tracks, with more than 160 companies enrolled, per MedTech Dive.
Boston Scientific's recovery is now dated: a September 10 company release says manufacturing, order fulfillment, and shipping are fully restored; the guidance arithmetic lands October 28.
Novo Nordisk announced an AI collaboration with Anthropic, terms undisclosed, and House China committee staff said drugmakers are cooperating with the trial site probe, per Endpoints. (Disclosure: this newsletter is drafted with Anthropic's Claude.)
📖 In Today's Full Analysis
Be sure to read the full article for all the details, including:
The full ORIGIN 3 endpoint table and the three mechanism IgAN comparison against Voyxact and povetacicept
The Sironax term sheet and what Novartis actually acquired
Skyhawk's complete fifteen month dataset with the external control caveats spelled out
The bounce ledger across seven tickers, separating disclosed causes from silent moves
🔒 BioMed Nexus Pro
In Today's Pro Brief...
🧠 The IgAN endgame: why Vera's most valuable disclosure was a date, not a hazard ratio, and the number povetacicept now has to beat on November 30
📊 The bounce ledger, itemized: what Wednesday's silent recoveries prove about who was selling Tuesday, and the single level that tells you Definium's round trip is complete
🧪 Novartis' external brain: the pattern connecting four straight R&D failures to a $125 million delivery platform, and where the external control era pays next
🎯 Plus the week's coming catalysts, with the full calendar returning Friday
Thursday the Amylyx meter runs out, and Friday the FDA answers on UX111 whether anyone is ready or not. Silence has stopped being free in this tape, and we will tell you what each one cost. What are you watching? Reply to this email.
Sponsorship slots for 2026 are limited. See packages and pricing →
NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →